BR112022021203A2 - Modulação de enzima e via com compostos sulfidrila e seus derivados - Google Patents

Modulação de enzima e via com compostos sulfidrila e seus derivados

Info

Publication number
BR112022021203A2
BR112022021203A2 BR112022021203A BR112022021203A BR112022021203A2 BR 112022021203 A2 BR112022021203 A2 BR 112022021203A2 BR 112022021203 A BR112022021203 A BR 112022021203A BR 112022021203 A BR112022021203 A BR 112022021203A BR 112022021203 A2 BR112022021203 A2 BR 112022021203A2
Authority
BR
Brazil
Prior art keywords
relates
proteins
antibodies
derivatives
pathway
Prior art date
Application number
BR112022021203A
Other languages
English (en)
Portuguese (pt)
Inventor
Shao Zhixin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022021203A2 publication Critical patent/BR112022021203A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
BR112022021203A 2020-04-24 2021-04-23 Modulação de enzima e via com compostos sulfidrila e seus derivados BR112022021203A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171356 2020-04-24
PCT/EP2021/060637 WO2021214277A1 (en) 2020-04-24 2021-04-23 Enzyme and pathway modulation with sulfhydryl compounds and their derivatives

Publications (1)

Publication Number Publication Date
BR112022021203A2 true BR112022021203A2 (pt) 2022-12-06

Family

ID=70464886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021203A BR112022021203A2 (pt) 2020-04-24 2021-04-23 Modulação de enzima e via com compostos sulfidrila e seus derivados

Country Status (18)

Country Link
US (2) US20230265204A1 (https=)
EP (2) EP4400515A3 (https=)
JP (3) JP2023522417A (https=)
KR (1) KR20230005172A (https=)
CN (1) CN115427443A (https=)
AR (1) AR121918A1 (https=)
AU (1) AU2021258475A1 (https=)
BR (1) BR112022021203A2 (https=)
CA (1) CA3178472A1 (https=)
CL (2) CL2022002885A1 (https=)
CR (2) CR20250142A (https=)
IL (1) IL296664A (https=)
MX (1) MX2022013173A (https=)
PE (1) PE20230078A1 (https=)
SA (1) SA522441031B1 (https=)
TW (2) TW202547878A (https=)
WO (1) WO2021214277A1 (https=)
ZA (1) ZA202210643B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3334167A1 (de) 1983-09-21 1985-04-04 Siemens AG, 1000 Berlin und 8000 München Halbleiterdiode
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
GB9717926D0 (en) 1997-08-22 1997-10-29 Micromass Ltd Methods and apparatus for tandem mass spectrometry
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP2002502086A (ja) 1998-01-23 2002-01-22 アナリティカ オブ ブランフォード インコーポレーテッド 表面からの質量分光測定
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2471551C (en) * 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
PT2592148T (pt) 2007-10-12 2018-11-12 Hoffmann La Roche Expressão proteica de múltiplos ácidos nucleicos
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
KR20110013687A (ko) 2009-08-03 2011-02-10 삼성모바일디스플레이주식회사 유기전계발광표시장치 및 그의 구동방법
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
NO2748201T3 (https=) 2011-08-23 2018-05-12
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP2017501848A (ja) * 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
BR112016017660B1 (pt) * 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3051839A1 (en) * 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
CA3108986A1 (en) * 2018-08-09 2020-02-13 Ventana Medical Systems, Inc. Determination of parkinson's disease

Also Published As

Publication number Publication date
WO2021214277A1 (en) 2021-10-28
KR20230005172A (ko) 2023-01-09
JP2025072512A (ja) 2025-05-09
CA3178472A1 (en) 2021-10-28
CL2022002885A1 (es) 2023-06-16
CR20250142A (es) 2025-10-30
ZA202210643B (en) 2023-06-28
JP2025157400A (ja) 2025-10-15
PE20230078A1 (es) 2023-01-11
TWI908792B (zh) 2025-12-21
AR121918A1 (es) 2022-07-20
EP4400515A3 (en) 2024-10-23
IL296664A (en) 2022-11-01
CN115427443A (zh) 2022-12-02
JP2023522417A (ja) 2023-05-30
EP4139349A1 (en) 2023-03-01
US20250353922A1 (en) 2025-11-20
US20230265204A1 (en) 2023-08-24
AU2021258475A1 (en) 2022-10-20
EP4400515A2 (en) 2024-07-17
TW202547878A (zh) 2025-12-16
CL2025000038A1 (es) 2025-05-23
SA522441031B1 (ar) 2025-05-15
TW202206459A (zh) 2022-02-16
MX2022013173A (es) 2022-11-30
CR20220531A (es) 2022-11-28

Similar Documents

Publication Publication Date Title
BR112022021203A2 (pt) Modulação de enzima e via com compostos sulfidrila e seus derivados
Chini et al. The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging
BR112020026125A8 (pt) Compostos oligonucleotídeos superiores ou 5'-cap- trinucleotídeo e seus usos na estabilização de rna, expressão de proteínas e em terapia
Sun et al. Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression
Bjarnason et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
McNally et al. Optogenetic manipulation of an ascending arousal system tunes cortical broadband gamma power and reveals functional deficits relevant to schizophrenia
Peyvandi et al. Critical role of SDF-1/CXCR4 signaling pathway in stem cell homing in the deafened rat cochlea after acoustic trauma
BR112023020167A2 (pt) Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
Cheleschi et al. Hydrostatic pressure regulates oxidative stress through microRNA in human osteoarthritic chondrocytes
BR112022008201A2 (pt) Degradação de proteínas de superfície usando agente de ligação biespecífico
Gualdani et al. How TRPC channels modulate hippocampal function
Codenotti et al. Hyperactive Akt1 signaling increases tumor progression and DNA repair in embryonal rhabdomyosarcoma RD line and confers susceptibility to glycolysis and mevalonate pathway inhibitors
Grañé-Boladeras et al. Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir
Rao et al. Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms
Wang et al. A novel method to limit breast cancer stem cells in states of quiescence, proliferation or differentiation: Use of gel stress in combination with stem cell growth factors
Konířová et al. Differentiation induction as a response to irradiation in neural stem cells in vitro
Nakahara et al. The role of PML in hematopoietic and leukemic stem cell maintenance
Yang et al. Increased activity of CHK enhances the radioresistance of MCF-7 breast cancer stem cells
Heinen et al. Effects of Lonomia obliqua caterpillar venom upon the proliferation and viability of cell lines
JOP20230173A1 (ar) أشطر إطالة العمر-النصفي وطرق استخدامها
Song et al. A glycolytic shunt via the pentose phosphate pathway is a metabolic checkpoint for nervous system sensory homeostasis and axonal regeneration
Kusuyama et al. Low intensity pulsed ultrasound (LIPUS) maintains osteogenic potency by the increased expression and stability of Nanog through spleen tyrosine kinase (Syk) activation
Qi et al. Effects of hyperbaric oxygen treatment on gastric cancer cell line SGC7901
Guardamagna et al. Asparagine and glutamine deprivation alters ionizing radiation response, migration and adhesion of a p53null colorectal cancer cell line